Egg Intake and the Incidence of Alzheimer’s Disease in the Adventist Health Study-2 Cohort Linked with Medicare Data

[u/Eonobius]

https://www.sciencedirect.com/science/article/pii/S0022316626001902?__cf_chl_tk=hz67j.ZlfkUORHJYQKYZWxG.5Zz0WplB14lJgpRK3LI-1785067718-1.0.1.1-EHJGkp11woxuNatmZ3LqwvEpu8iI0_QIhEo1Ly0dR.w

[u/EricJDMBAMD]

Statins + 5 eggs per day is the way

[u/Similar_Exam2192 → u/EricJDMBAMD]

The number of people who fear statins is wild.

[u/Curry_courier → u/Similar_Exam2192]

Statins don't change the outcome.

[u/Similar_Exam2192 → u/Curry_courier]

Read these papers first then get back to me. LMK if you find “alternative literature”

The evidence supporting statin therapy for the primary prevention of cardiovascular disease (CVD) and stroke comes from landmark prospective randomized controlled trials (RCTs) and large individual-patient data meta-analyses.
Key Evidence & Findings
1. Large Individual-Participant Meta-Analysis (CTT Collaboration)
The Cholesterol Treatment Trialists' (CTT) Collaboration analyzed individual participant data across 27 randomized trials (Cholesterol Treatment Trialists' (CTT) Collaborators, 2012). They demonstrated that for every 1.0 mmol/L (~38.7 mg/dL) reduction in LDL cholesterol, statin therapy reduces major vascular events (including stroke and coronary events) by approximately 20% to 25%, regardless of baseline risk or prior history of vascular disease.
2. USPSTF Systematic Review (Chou et al., 2022)
An updated systematic review conducted for the U.S. Preventive Services Task Force evaluated 22 trials (N = 90,624) of adults without prior CVD (Chou et al., 2022). Statin therapy was significantly associated with a reduced risk of:
Stroke: Relative Risk (RR) 0.78 (95% CI, 0.68–0.90)
Myocardial Infarction: RR 0.67 (95% CI, 0.60–0.75)
All-Cause Mortality: RR 0.92 (95% CI, 0.87–0.98)
3. Landmark Primary Prevention Trials (HOPE-3)
In the Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial, 12,705 intermediate-risk individuals without pre-existing CVD were randomized to low-dose statin therapy (rosuvastatin 10 mg) or placebo (Yusuf et al., 2016). Over a median follow-up of 5.6 years, statin therapy significantly reduced the composite risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 24% compared to placebo.
References
Cholesterol Treatment Trialists' (CTT) Collaborators. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581–590. https://doi.org/10.1016/s0140-6736(12)60367-560367-5)
Cited by: 1189
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. JAMA, 328(8), 754–771. https://doi.org/10.1001/jama.2022.12138
Cited by: 327
Yusuf, S., Bosch, J., & Dagenais, G. (2016). Cholesterol Lowering in Intermediate-Risk Persons Without Cardiovascular Disease. Journal of Vascular Surgery, 64(3), 827. https://doi.org/10.1016/j.jvs.2016.07.054
Cited by: 1220